A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 3, 2006, Pages 368-373

  Ichiki, Masao ^a   Kawasaki, Masayuki ^b   Takayama, Koichi ^c   Ninomiya, Kiyoshi ^d   Kuba, Mutsuo ^e   Iwami, Fumiyuki ^f   Miyazaki, Naoki ^g   Oishi, Kazunori ^h   Takeo, Sadanori ^a   Aizawa, Hisamichi ⁱ   Nakanishi, Yoichi ^c  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^e National Hospital Organization Okinawa National Hospital   (Japan)

^f Minami Kyushu Hospital   (Japan)

^g STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biweekly schedule; Carboplatin; Non small cell lung cancer; Paclitaxel; Phase II study

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANAPHYLACTIC SHOCK; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 33744487395     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0168-3     Document Type: Article

References (23)

1. Belani CP, Aisner J, Hiponia D, Ramanathan R (1996) Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study. Semin Oncol 23(5 Suppl 12):19-21
2. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM (2003) Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21:2933-2939
3. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ (1999) Phase I trial, including pharmcokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17:676-684
4. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol 18:3101-3107
5. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
6. Evans WK, Earle CC, Stewart DJ, Dahrouge S, Tomiak E, Goss G, Logan D, Goel R, Gertler SZ, Dulude H (1997) Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer 18:83-94
7. Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D (2001) Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res 21:1487-1494
8. Greco FA, Hainsworth JD (1998) One-hour paclitaxel plus carboplatin for advanced non-small-cell lung cancer. Oncology 12(1 Suppl 2):71-73
9. Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, Thomas M, Greco FA (1998) One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer 34:654-658
10. Helsing M, Thaning L, Sederholm C, Sederholm C, Lamberg K, Martinsson JE, Ek L, Mansson T, Andersson L, Hero U, Anjedani D, Svennson G (1999) Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Lung Cancer 24:107-113
11. Ichiki M, Gohara R, Fujiki R, Hoashi S, Rikimaru T, Aizawa H (2003) Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 52:67-72
12. Jelliffe RW (1973) Creatinine clearance: badside estimate. Ann Interm Med 79:604-605
13. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, DeVore RF III (1996) Paclitaxel plus carboplatin in advanced non- small-cell lung cancer: a phase II trial. J Clin Oncol 14:2054-2060
14. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 19:3210-3218
15. Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA Jr (1997) A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 3:1117-1123
16. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, Negoro S, Ariyoshi Y, Nakagawa K, Fukuoka M (2004) The four-arm cooperative study (FACS) for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:618s
17. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity,response, and survival analysis. J Clin Oncol 13:1860-1870
18. National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0, January 30, 1998) (1999) Gan To Kagaku Ryoho 26:1084-1144 (in Japanese)
19. Ramalingam S, Perry MC, Larocca RV, Rinaldi DA, Gable P, Tester WJ, Belani CP (2005) Outcome of elderly (≥ 70 years) non-small cell lung cancer (NSCLC) patients on a mulicenter, phase III randomized trial comparing weekly vs. standard-schedules of paclitaxel (P) plus carboplatin (C). Proc Am Soc Clin Oncol 23:657s
20. Roychowdhury DF, Desai P, Zhu YW (1997) Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. Semin Oncol 24(4 Suppl 12):37-40
21. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
22. Shyr Y, Choy H, Cmelak P, Mohr P, Johnson DH (1998) Pattern of practice survey non-small cell lung cancer (NSCLC) in US. Proc Am Soc Clin Oncol 17:463a
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216